1) Sada KE, Yamamura M, Harigai M, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014
2) 有村義宏, 他 : ANCA関連血管炎診療ガイドライン 2017, p58-60, 診断と治療社, 東京, 2017
3) 丸山彰一 (監修) : エビデンスに基づく急性進行性腎炎症候群 (RPGN) 診療ガイドライン 2017, 東京医学社, 東京, 2017
4) 新田孝作, 他 : わが国の慢性透析療法の現況 (2017年12月31日現在). 透析会誌 51 : 699-766, 2018
5) Jennette JC, Nachman PH : ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 12 : 1680-1691, 2017
6) Chen SF, Wang H, Huang YM, et al : Clinicopathologic characterisitics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin J Am Soc Nephrol 10 : 750-758, 2015
7) Trejo MW, van Daalen E, Wolterbeek R, et al : Differences in renal histopathology between PR3-ANCA-associated vasculitis and MPO-ANCA-associated vasculitis. Rheumatology 58 (Suppl 2) : ii50-ii51, 2019 (abstract)
8) Joh K, Muso E, Shigematsu H, et al : Renal pathology of ANCA-related vasculitis : proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 12 : 277-291, 2008
10) Chen YX, Xu J, Pan XX, et al : Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis : a study of 186 patients and metaanalysis. J Rheumatol 44 : 304-313, 2017
11) Neumann I, Kain R, Regele H, et al : Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 20 : 96-104, 2005
12) Chen Y, Bao H, Liu Z, et al : Risk factors for renal survival in Chinese patients with myeloperoxidase-ANCA-associated GN. Clin J Am Soc Nephrol 12 : 417-425, 2017
13) Menez S, Hruskova Z, Scott J, et al : Predictors of renal outcomes in sclerotic class anti-neutrophil cytoplasmic antibody glomerulonephritis. Am J Nephrol 48 : 465-471, 2018
14) Berden AE, Jones RB, Erasmus DD, et al : Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-asscociated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23 : 313-321, 2012
15) Brix SR, Noriega M, Tennstedt P, et al : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94 : 1177-1188, 2018
16) Yamagata K, Usui J, Nagata M, et al : Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. Clin Exp Nephrol 23 : 387-394, 2019
17) Ntatsaki E, Carruthers D, Chakravarty K, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53 : 2306-2309, 2014
20) Jones RB, Furuta S, Tervaert JW, et al : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis : 2-year results of a randomised trial. Ann Rheum Dis 74 : 1178-1182, 2015
21) Geetha D, Specks U, Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculi tis with renal involvement. J Am Soc Nephrol 26 : 976-985, 2015
22) McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al : Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34 : 63-73, 2019
23) Rovin BH, Caster DJ, Cattran DC, et al : Management and treatment of glomerular diseases (part 2) : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95 : 281-295, 2019
24) Jayne DR, Gaskin G, Rasmussen N, et al : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 : 2180-2188, 2007
25) Walsh M, Merkel P, Peh CA, et al : The effect of plasma exchange on end-stage renal disease and death in patients with severe ANCA-associated vasculitis (PEXIVAS). Nephrol Dial Transplant 33 : i636, 2018
26) Moura MC, Mira MI, Massat AE, et al : Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe renal disease. Rheumatology 58 (Supple 2) : 128-129, 2019
28) Terrier B, Pagnoux C, Perrodeau E, et al : Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77 : 1150-1156, 2018
29) Jones RB, Hiemstra TF, Ballarin J, et al : Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis : a randomised, non-inferiority trial. Ann Rheum Dis 78 : 399-405, 2019
30) Charles P, Terrier B, Perrodeau E, et al : Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission : results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77 : 1143-1149, 2018
31) Xiao H, Dairaghi DJ, Powers JP, et al : C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25 : 225-231, 2014
32) Jayne DRW, Bruchfeld AN, Harper L, et al : Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28 : 2756-2767, 2017
33) Kemna MJ, Damoiseaux J, Austen J, et al : ANCA as a predictor of relapse : useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 26 : 537-542, 2015
34) Rhee RL, Davis JC, Ding L, et al : The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin J Am Soc Nephrol 13 : 251-257, 2018